Studies have revealed that elevated homocysteine levels can cause damage to motor neurons through multiple neurotoxic mechanisms, thus leading to the pathogenesis of amyotrophic lateral sclerosis (ALS). One way by which homocysteine levels are increased in the body is the consequence of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms. Therefore, to address this question, we studied the MTHFR C677T and A1298C polymorphisms in 437 sporadic ALS (SALS) and 439 healthy controls to learn whether they were associated with SALS. The overall SALS were not associated with MTHFR C677T and A1298C polymorphisms (v 2 = 1.378; p = 0.502; v 2 = 1.304; p = 0.521, respectively). However, when we stratified results in terms of gender, we found that the MTHFR C677T polymorphism (v 2 = 6.376; p = 0.041), T677T genotype (v 2 = 5.508; p = 0.019; odds ratio [OR] = 2.561; 95% confidence interval [CI] = 1.142-5.744), C677C/A1298A (v 2 = 5.216; p = 0.022; OR = 0.424, 95% CI = 0.199-0.900), and T677T/A1298A (v 2 = 6.639; p = 0.010; OR = 2.900; 95% CI = 1.252-6.717) compound genotypes were associated with SALS in female patients only. Moreover, stratification of SALS according to the onset of disease indicated that there was no association between MTHFR C677T (v 2 = 1.565; p = 0.457; A1298C v 2 = 3.461; p = 0.177) polymorphisms and overall spinal onset SALS. Further stratification analysis according to gender revealed that there was a remarkable association between MTHFR C677T (v 2 = 9.728, p = 0.008), T677T genotype (v 2 = 7.820; p = 0.005; OR = 3.126; 95% CI = 1.361-7.178) and T allele (v 2 = 5.000; p = 0.025; OR = 1.711; 95% CI = 1.067-2.745), and T677T/A1298A compound genotype (v 2 = 9.108; p = 0.003; OR = 3.540; 95% CI = 1.494-8.387) and spinal onset female SALS only. Likewise, there was also association between MTHFR A1298C polymorphism (v 2 = 5.946; p = 0.051) and the C1298C genotype (v 2 = 5.282; p = 0.022; OR = 2.524; 95% CI = 1.125-5.658), and the C677T/C1298C compound genotype (v 2 = 7.155; p = 0.007; OR = 1.045; 95% CI = 0.983-1.112) and bulbar onset SALS only in women. In conclusion, the evidence we provide here clearly shows that MTHFR C677T and A1298C polymorphisms are genetic risk factors for SALS in women in a gender-specific manner whether they are of spinal or bulbar onset.
Introduction
A myotrophic lateral sclerosis (ALS) is a fatal adult onset neurodegenerative disorder of unknown etiology characterized by rapidly progressive paralysis, leading ultimately to death within 3 to 5 years of symptom onset (Mulder et al., 1986) . The incidence of ALS is 1-2 in 100,000 people worldwide (Wijesekera and Leigh, 2009 ). There is evidence that ALS is more common in men than women, and the clinical features of the disease are markedly influenced by gender (McCombe and Henderson, 2010) . Familial ALS and sporadic ALS (SALS) are influenced by genetics and environmental factors (Fang et al., 2009; Sutedja et al., 2009; Wijesekera and Leigh, 2009 ). Due to the differential clinical presentations, patients with ALS can be placed in different groups with common features (Talman et al., 2009) .
The methylenetetrahydrofolate reductase (MTHFR) gene is located on chromosome 1 (1p36.3), contains 11 exons, and encodes the methylenetetrahydrofolate reductase (EC 1.5.1.20) enzyme that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the methyl donor in the remethylation of homocysteine to methionine. Methylenetetrahydrofolate reductase is the key enzyme in folate metabolism. Two functional polymorphisms in the MTHFR gene have a highly variable prevalence in different ethnic populations in the world . MTHFR C677T (rs1801133) and A1298C (rs1801131) polymorphisms are implicated in a variety of diseases (Kara et al., 2003; Sazci et al., 2003 Sazci et al., , 2004 Sazci et al., , 2005a Sazci et al., , 2006 Sazci et al., , 2007 . The C677T (Ala222Val) polymorphism in exon 4 results in alanine to valine replacement at codon 222 (Frosst et al., 1995) . The A1298C (Glu429Ala) polymorphism in exon 7 results in glutamate to alanine replacement at codon 429 (van der Put et al., 1998) . Apparently, these two polymorphisms alter enzyme specific activity; the T677T variant having only 30% and the C677T variant having only 65% enzyme specific activity when compared with the C677C variant (Frosst et al., 1995) ; the C1298C variant having only 60% enzyme specific activity when compared with the A1298A variant (van der Put et al., 1998) . Consequently, as the enzyme specific activity is reduced in the rare variant, the homocysteine levels are drastically increased, thus causing hyperhomocysteinemia.
In our previous observation presented in the 13th meeting of ALS/MND in Dublin, 2005, using 52 ALS patients and 278 controls, we were able to show an association between the MTHFR polymorphism and ALS (Sazci et al., 2005b) . Since then, we continued collecting SALS patients to evaluate the association between MTHFR C677T and A1298C polymorphisms. In this regard, we collected 437 SALS patients and 439 controls. We confirmed our previous results in a genderspecific manner in which we found an association only between female SALS and MTHFR T677T, C1298C genotype and T677T/A1298A compound genotype.
Materials and Methods

Subjects
The study population included 437 SALS patients (mean age: 53.67 -13.246; age range: 15 to 89; median age: 55.00) and 439 unrelated healthy controls (mean age: 54.16 -16.809; age range: 15 to 80; median age: 54.00) ( Table 1) . The 437 SALS patients were from the outpatient clinics of the University of Istanbul. The diagnosis of the ALS patients was made possible after the attending neurologist had supplied details of the neurological examination and an electromyographic report. Diagnosis of the patients was either definite or probable SALS by modified Airlie House El Escorial criteria (Brooks et al., 2000) . Cranial and cervical magnetic resonance imaging were also utilized in the diagnosis whenever needed. The control subjects who were recruited into the study underwent a clinical examination at the University Hospital of Istanbul, Turkey. The institutional review board approved the study. All subjects gave their written informed consent to participate in the study.
Genetic testing
Genomic DNA was isolated from blood of subjects using a conventional method. Genotyping was carried out as described .
Statistical analysis
Allele and genotype frequencies were compared between cases and controls using the v 2 test, and student's t-test was used for age difference. The odds ratio (OR) and 95% confidence intervals (CIs) were calculated to evaluate the effects of the different genotypes and alleles using conditional logistic regression. Significance was set at p < 0.05. SPSS(v17) was utilized in the statistical analysis. The Hardy-Weinberg equilibrium was verified for all tested controls and cases.
Results
Clinical data for SALS patients are given in Table 1 . The frequencies of MTHFR 677T and MTHFR 1298C alleles are 34.43% in SALS and 28.93% in controls and 34.78% in SALS and 37.36 in controls, respectively. The frequencies of MTHFR gene C677C, C677T, and T677T genotypes are 50.1%, 38.9%, and 11.0% in SALS and 50.8%, 40.5%, and 8.7% in controls, respectively. The frequencies of MTHFR A1298A, A1298C, and C1298C genotypes are 41.9%, 46.7%, and 11.4% in SALS and 38.7%, 47.8%, and 13.4% in controls, respectively. There was no association between MTHFR gene C677T polymorphism and overall SALS (v 2 = 1.378; p = 0.502). However, there was an increase in the T677T genotype from 8.7% in controls to 11% in overall SALS. Likewise, there was no association between MTHFR gene A1298C polymorphism and overall SALS (v 2 = 1.304; p = 0.521). Although there was no association between compound genotypes of MTHFR gene and overall SALS (v 2 = 3.998; p = 0.677), there was an increase in MTHFR T677T/A1298A genotype from 8.2% in controls to 10.7% in overall SALS (OR = 1.381; 95% CI = 0.877-2.175). Interestingly, we did not obtain individuals with T677T/A1298C and T677T/C1298C compound genotypes either in overall SALS or in controls. Stratification analysis revealed a strong effect of gender on the association of MTHFR C677T polymorphism with risk of SALS in only female SALS given in Table 2 (v 2 = 6.376; p = 0.041). The association of MTHFR T677T genotype with SALS was statistically significant in women (v 2 = 5.508, p = 0.019; OR = 2.561; 95% CI = 1.142-5.744). Individuals with T677T genotype showed a 2.561 times increased risk for SALS. The MTHFR 677C allele was protective against SALS in women (OR = 0.390; 95% CI = 0.174-0.876; v 2 = 5.508; p = 0.019). The MTHFR A1298C polymorphism did not show any association with SALS in women (v 2 = 1.290; p = 0.525). Nonetheless, there was an increase in the frequency of MTHFR C1298C genotype from 12.3% in controls to 16.6% in SALS in women (v 2 = 1.239; p = 0.266; OR = 1.420; 95% CI = 0.764-2.637). The compound genotypes of MTHFR C677T/A1298C polymorphisms were associated with SALS in women (v 2 = 13.334; p = 0.038). The MTHFR C677C/ A1298A compound genotype was protective against SALS in women (OR = 0.424; 95% CI = 0.199-0.900; v 2 = 5.216; p = 0.022). Most importantly, the MTHFR T677T/A1298A compound genotype showed a remarkably increased risk for association with SALS in women (OR = 2.900; 95% CI = 1.252-6.717; v 2 = 6.639; p = 0.010). The T677T genotype was 4.9% in controls and 13% in female SALS. On the contrary, finally, MTHFR C677T and A1298C polymorphisms did not show any association with SALS in male patients (v 2 = 1.055; p = 0.590; v 2 = 5.288; p = 0.071), respectively. There were only 364 SALS with spinal onset. There was no association between spinal onset SALS and MTHFR C677T and A1298C polymorphisms (v 2 = 1.565; p = 0.457; v 2 = 3.461; p = 0.177) and spinal onset male SALS and MTHFR C677T and A1298C polymorphisms (v 2 = 1.897; p = 0.387; v 2 = 4.580; p = 0.101). Nevertheless, there was a strong association between spinal onset in women and MTHFR C677T polymorphisms (v 2 = 9.728; p = 0.008). The MTHFR C677C genotype presented protection against SALS in women with spinal onset (v 2 = 5.000; p = 0.025; OR = 0.584; 95% CI = 0.364-0.937). However, the MTHFR T677T genotype showed a robust association with SALS in women with spinal onset (v 2 = 7.820; p = 0.005; OR = 3.126; 95% CI = 1.361-7.178). Moreover, there was an MTHFR 677C allele (v 2 = 7.820, p = 0.005; OR = 0.320; 95% CI = 0.139-0.734) association as well as a 677T allele (v 2 = 5.000; p = 0.025; OR = 1.711; 95% CI = 1.067-2.745) association in women with spinal onset. The MTHFR A1298C polymorphism was not associated with spinal onset SALS in women (v 2 = 0.492; p = 0.782). However, there was a strong association between the MTHFR T677T/A1298A compound genotype and spinal onset SALS in women (v 2 = 9.108; p = 0.003; OR = 3.548; 95% CI = 1.494-8.387) ( Table 3) (Table 4) .
Discussion
In our previous study, we showed an association with MTHFR gene polymorphisms C677T and A1298C and ALS in which we used 52 ALS patients and 278 controls (Sazci et al., 2005b) . We confirmed our previous findings in a genderspecific manner using 437 SALS and 439 controls only in patients with female SALS. The MTHFR C677T polymorphism was associated with female SALS (v 2 = 6.376; p = 0.041) in which we were able to show an association between MTHFR T677T genotype (v 2 = 5.508; p = 0.019; OR = 2.561; 95% CI = 1.142-5.744) and SALS in female patients. The MTHFR 677C allele was protective against SALS (v 2 = 5.508; p = 0.019; OR = 0.390; 95% CI = 0.174-0.876). MTHFR C677T/A1298C polymorphisms were associated with SALS in female patients (v 2 = 13.334; p = 0.038). Individuals with MTHFR C677C/ A1298A compound genotypes revealed protection against SALS in female patients (v 2 = 5.216; p = 0.038; OR = 0.424; 95% 718 SAZCI ET AL. CI = 0.199-0.900). However, individuals with MTHFR T677T/ A1298A compound genotype showed a statistically remarkable association with SALS in female patients (v 2 = 6.639, p = 0.010, OR = 2.900; 95% CI = 1. 252-6.717) . Surprisingly, we did not see individuals with MTHFR T677T/A1298C or T677T/C1298C compound genotypes in either SALS or controls.
Recently, Kü hnlein et al. (2011) have reported that the MTHFR C677T polymorphism was not associated with spinal ALS, but with bulbar onset (v 2 = 5.39; p = 0.020). In their study, they could not find an association between MTHFR A1298C polymorphism and SALS. There is evidence that bulbar onset is more common in women than men. However, they did not evaluate gender-specific associations in their study. In our study, spinal onset is seen in 83% of SALS patients. Bulbar onset is only seen in 17% of SALS patients (Table 1 ). However, all SALS patients, whether they were spinal or bulbar onset by origin, eventually develop bulbar symptoms.
Recently, Ricci et al. (2011) have also reported that the MTHFR C677T polymorphism was not associated with ALS in an Italian population consisting of 450 ALS patients and 700 controls.
Although data on how homocysteine causes damage to motor neurons are not available, it is likely that damage may be induced by oxidative stress through mediated copper ROS production. Another mechanism by which damage is caused to motor neurons is through the stimulation of both Nmethyl-D-aspartate (NMDA) and non-NMDA receptors, thus leading to calcium accumulation in motor neurons, resulting in cell death.
High plasma levels of homocysteine have been shown to be associated with neurodegenerative disorders such as Alzheimer's disease (Seshadri et al., 2002; Morris, 2003) , mild cognitive impairment (Quadri et al., 2004 (Quadri et al., , 2005 , and Parkinson's disease, particularly in patients treated with L-dopa (Postuma and Lang, 2004) .
Elevated homocysteine levels have been reported to induce a selective dose-dependent cytotoxic effect on motor neurons transfected with the SOD1 G93A mutant (Sung et al., 2002; Zhang et al., 2008 Zhang et al., , 2010 . This toxic effect by homocysteine was prevented by the addition of antioxidants and copper chelators, but not by glutamate receptor blockers. Homocysteine levels in the body are increased as people get older and also by environmental factors. Therefore, elevated homocysteine levels may have a role in the progression of ALS rather than its pathogenesis (Zoccolella et al., 2008 (Zoccolella et al., , 2010 .
The expression of TP53 (NM_000546) was increased by 2.1-fold in the whole spinal cord and by 2.7-fold in the ventral horn of ALS patients (Eve et al., 2007) . However, this increase was not associated with the TP53 Arg72Pro polymorphism in patients with SALS (Ergul et al., 2011) . Apart from MTHFR gene polymorphisms involved in the elevation of homocysteine levels in plasma, decreased activity of paraoxonase may also increase the risk for ALS. Consequently, in both cases, homocysteine levels are additively increased (Saeed et al., 2006) . Homocysteine, apart from its vascular effects, possesses a number of neuropathological pathways such as free radical formation, cytosolic calcium accumulation, mitochondrial dysfunction, apoptotic pathway activation, and excitotoxic amino-acid-mediated cellular damage. These pathways have 
also been shown to be implicated in the pathogenesis of ALS (Kruman et al., 2000; Rowland and Shneider, 2001; Jara-prado et al., 2003; Robert et al., 2005; Obeid and Herrmann, 2006) . A different line of evidence has shown that familial and SALS have similar pathological pathways (Al-Chalabi and Leigh, 2000) .
In conclusion, in the present study, MTHFR gene T677T genotype, C677C/A1298A, and T677T/A1298A compound genotypes were associated with SALS in female patients only. The reason why association was only seen in women whether they had spinal or bulbar onset is a matter of another study. It appears that although there is no curative therapy for ALS, MTHFR polymorphisms and homocyteine levels should be checked, and therapy should also be designed to normalize homocysteine levels with folic acid (Stanger et al., 2009) . 
